Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
[Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2)].
Gunther Klautke
Published: 202610.1007/s00066-025-02500-1
No abstract available for this study.